NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $24.10 +0.01 (+0.04%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$23.86▼$24.8650-Day Range$18.04▼$24.0952-Week Range$14.56▼$28.75Volume543,069 shsAverage Volume1.17 million shsMarket Capitalization$3.44 billionP/E RatioN/ADividend YieldN/APrice Target$40.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside67.4% Upside$40.33 Price TargetShort InterestBearish6.05% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment1.17Based on 5 Articles This WeekInsider TradingSelling Shares$710,274 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.77) to ($2.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.05 out of 5 starsMedical Sector186th out of 936 stocksBiological Products, Except Diagnostic Industry22nd out of 154 stocks 3.4 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Denali Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.05% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 4.58%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 2.9 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $710,274.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.77) to ($2.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -25.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -25.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesJuly 4, 2024 | insidertrades.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Sells $14,991.52 in StockJuly 19, 2024 | americanbankingnews.comDenali Therapeutics Inc. (NASDAQ:DNLI) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 8, 2024 | investorplace.com3 Longevity Stocks to Buy for Anti-Aging BreakthroughsJune 6, 2024 | seekingalpha.comDenali: Cash, Big Pharma Partnerships And High Potential For MPS-II Do Not Warrant A BuyJune 3, 2024 | globenewswire.comDenali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease TherapiesMay 13, 2024 | seekingalpha.comDenali Therapeutics: MPS Treatment Program Continues With End Of 2024 DataMay 13, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Denali Therapeutics (DNLI)July 27, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 10, 2024 | markets.businessinsider.comPositive Outlook for Denali Therapeutics: Accelerated Approval and Financial Strategy Strengthening Market PositionMay 10, 2024 | markets.businessinsider.comOptimistic Outlook for Denali Therapeutics: Buy Rating Affirmed Amidst Positive ERT Developments and Strong Pipeline ProgressMay 9, 2024 | finance.yahoo.comDenali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)May 7, 2024 | finance.yahoo.comDenali Therapeutics Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic ShiftsMay 7, 2024 | finance.yahoo.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 7, 2024 | globenewswire.comDenali Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 2, 2024 | markets.businessinsider.comBuy Recommendation for DNLI: Promising Safety and Efficacy of Denali’s ALS Drug DNL343May 1, 2024 | globenewswire.comDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform TrialApril 29, 2024 | finance.yahoo.comIs There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?See More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees445Year Founded2015Price Target and Rating Average Stock Price Target$40.33 High Stock Price Target$95.00 Low Stock Price Target$22.00 Potential Upside/Downside+67.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net MarginsN/A Pretax Margin-46.45% Return on Equity-11.46% Return on Assets-10.40% Debt Debt-to-Equity RatioN/A Current Ratio11.79 Quick Ratio11.79 Sales & Book Value Annual Sales$330.53 million Price / Sales10.40 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book3.25Miscellaneous Outstanding Shares142,610,000Free Float131,343,000Market Cap$3.44 billion OptionableOptionable Beta1.40 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $802.29kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsProthenaNASDAQ:PRTAREGENXBIONASDAQ:RGNXCytokineticsNASDAQ:CYTKBio-TechneNASDAQ:TECHQiagenNYSE:QGENView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 237,636 shares on 7/26/2024Ownership: 1.080%Baillie Gifford & Co.Sold 277,632 shares on 7/25/2024Ownership: 9.651%China Universal Asset Management Co. Ltd.Sold 9,968 shares on 7/20/2024Ownership: 0.012%MONECO Advisors LLCBought 8,700 shares on 7/19/2024Ownership: 0.006%Hamilton Lane Advisors LLCBought 25,657 shares on 7/17/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $21.46 at the beginning of 2024. Since then, DNLI stock has increased by 12.3% and is now trading at $24.10. View the best growth stocks for 2024 here. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) issued its earnings results on Tuesday, May, 7th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.01. What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' top institutional shareholders include Baillie Gifford & Co. (9.65%), Bank of New York Mellon Corp (1.08%), Clarius Group LLC (0.29%) and Hamilton Lane Advisors LLC (0.02%). Insiders that own company stock include Marc Tessier-Lavigne, Alexander O Schuth, Ryan J Watts, Carole Ho, Vicki L Sato and Steve E Krognes. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP) and Anavex Life Sciences (AVXL). This page (NASDAQ:DNLI) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.